• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上皮性卵巢癌的化疗。

Chemotherapy in epithelial ovarian cancer.

机构信息

Division of Medical Oncology, Department of Urology and Gynecology, National Cancer Institute of Naples, Via Mariano Semmola, 80131 Naples, Italy.

出版信息

Cancer Lett. 2011 Apr 28;303(2):73-83. doi: 10.1016/j.canlet.2011.01.026. Epub 2011 Feb 24.

DOI:10.1016/j.canlet.2011.01.026
PMID:21353386
Abstract

Epithelial ovarian cancer is the most common type of ovarian cancer; usually occurs in women older than 50years, and because 75% of cases are diagnosed at stage III or IV it is associated with a poor prognosis. Treatment of ovarian cancer is based on the integration of surgery and chemotherapy. Chemotherapy plays a major role both in the adjuvant treatment and in the care of patients with advanced disease. Several active drugs have been introduced in the treatment of ovarian cancer in the last decades and novel targets and agents are under evaluation.

摘要

上皮性卵巢癌是最常见的卵巢癌类型;通常发生在 50 岁以上的女性中,由于 75%的病例在 III 期或 IV 期诊断,因此预后不良。卵巢癌的治疗基于手术和化疗的结合。化疗在辅助治疗和晚期疾病患者的治疗中都起着重要作用。在过去几十年中,已经引入了几种治疗卵巢癌的有效药物,并且正在评估新的靶点和药物。

相似文献

1
Chemotherapy in epithelial ovarian cancer.上皮性卵巢癌的化疗。
Cancer Lett. 2011 Apr 28;303(2):73-83. doi: 10.1016/j.canlet.2011.01.026. Epub 2011 Feb 24.
2
Medical therapy of advanced malignant epithelial tumours of the ovary.晚期卵巢恶性上皮性肿瘤的医学治疗
Forum (Genova). 2000 Oct-Dec;10(4):323-32.
3
New options for the treatment of advanced ovarian cancer.晚期卵巢癌治疗的新选择。
Semin Oncol. 1997 Feb;24(1 Suppl 5):S5-2-S5-11.
4
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.辅助化疗和手术分期对早期卵巢癌的影响:欧洲癌症研究与治疗组织-卵巢肿瘤辅助化疗试验
J Natl Cancer Inst. 2003 Jan 15;95(2):113-25.
5
Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.上皮巨噬细胞集落刺激因子(CSF-1)及其受体的过表达:上皮性卵巢癌的不良预后因素,与基质CSF-1的保护作用形成对比。
Clin Cancer Res. 1997 Jun;3(6):999-1007.
6
Recent advances in the management of women with ovarian cancer.卵巢癌女性患者管理的最新进展
Minerva Ginecol. 2004 Feb;56(1):81-9.
7
Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature.早期卵巢癌的辅助化疗:文献综述
J Clin Oncol. 2007 Jul 10;25(20):2909-20. doi: 10.1200/JCO.2007.11.1013.
8
Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.早期高危型上皮性卵巢癌复发后的生存情况:一项妇科肿瘤学组研究。
Gynecol Oncol. 2010 Mar;116(3):307-11. doi: 10.1016/j.ygyno.2009.10.074. Epub 2009 Nov 27.
9
Investigational agents for epithelial ovarian cancer.上皮性卵巢癌的研究性药物。
Expert Rev Anticancer Ther. 2005 Oct;5(5):855-68. doi: 10.1586/14737140.5.5.855.
10
In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.使用人肿瘤集落形成试验对卵巢癌进行体外药物测试:体外反应与临床结果的比较。
Gynecol Oncol. 1994 Dec;55(3 Pt 2):S156-63. doi: 10.1006/gyno.1994.1356.

引用本文的文献

1
Identification of a novel chemotherapy benefit index for patients with advanced ovarian cancer based on Bayesian network analysis.基于贝叶斯网络分析确定晚期卵巢癌患者的新型化疗获益指数
PLoS One. 2025 May 27;20(5):e0322130. doi: 10.1371/journal.pone.0322130. eCollection 2025.
2
Epigenetic Modulation of Estrogen Receptor Signaling in Ovarian Cancer.卵巢癌中雌激素受体信号传导的表观遗传调控
Int J Mol Sci. 2024 Dec 28;26(1):166. doi: 10.3390/ijms26010166.
3
Clinical and translational advances in ovarian cancer therapy.卵巢癌治疗的临床和转化进展。
Nat Cancer. 2023 Sep;4(9):1239-1257. doi: 10.1038/s43018-023-00617-9. Epub 2023 Aug 31.
4
Development of Nomogram Models Based on Peripheral Blood Score and Clinicopathological Parameters to Predict Preoperative Advanced Stage and Prognosis for Epithelial Ovarian Cancer Patients.基于外周血评分和临床病理参数的列线图模型用于预测上皮性卵巢癌患者术前晚期阶段及预后的研究
J Inflamm Res. 2023 Mar 23;16:1227-1241. doi: 10.2147/JIR.S401451. eCollection 2023.
5
Increased levels of NETosis biomarkers in high-grade serous ovarian cancer patients' biofluids: Potential role in disease diagnosis and management.高等级浆液性卵巢癌患者生物流体中 NETosis 生物标志物水平升高:在疾病诊断和治疗中的潜在作用。
Front Immunol. 2023 Feb 3;14:1111344. doi: 10.3389/fimmu.2023.1111344. eCollection 2023.
6
Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo.安罗替尼在体外和体内对顺铂耐药卵巢癌均具有抑制作用。
Molecules. 2022 Dec 14;27(24):8873. doi: 10.3390/molecules27248873.
7
Targeting oxidative phosphorylation as an approach for the treatment of ovarian cancer.将氧化磷酸化作为治疗卵巢癌的一种方法。
Front Oncol. 2022 Sep 6;12:971479. doi: 10.3389/fonc.2022.971479. eCollection 2022.
8
Immunoprotecting Effects of Exercise Program against Ovarian Cancer: A Single-Blind, Randomized Controlled Trial.运动计划对卵巢癌的免疫保护作用:一项单盲随机对照试验
Cancers (Basel). 2022 Jun 5;14(11):2808. doi: 10.3390/cancers14112808.
9
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics.卵巢癌的预后及卡铂反应预测模型:一项基于临床和药物基因组学的单机构回顾性研究
Biomedicines. 2022 May 23;10(5):1210. doi: 10.3390/biomedicines10051210.
10
A risk model of gene signatures for predicting platinum response and survival in ovarian cancer.一种用于预测卵巢癌铂类药物反应和生存的基因标志物风险模型。
J Ovarian Res. 2022 Mar 31;15(1):39. doi: 10.1186/s13048-022-00969-3.